See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: May 31, 2006

Restless Legs Syndrome Bladder Cancer Hot Flash

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Restless Legs Syndrome

Do you have an uncomfortable or unpleasant sensation in your legs that gives you an urge to move them, particularly during periods of rest or inactivity? These symptoms describe a condition called Restless Legs Syndrome (RLS). Qualified participants in this clinical study of an investigative drug to treat RLS will receive all study-related care at no cost, and may be compensated up to $250 for time and travel.

The research site is in Anderson, S.C.

More information

Please see


Bladder Cancer

This study will evaluate intravenous cinflunine in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Volunteers who have had a relapse or progression within 12 months of prior cisplatin or carboplatin chemotherapy, or adequate performance status (Karnofsky greater or equal to 80) may qualify. Additional criteria apply.

Research sites are located worldwide.

More information

Please see


Hot Flash

This clinical trial is evaluating an investigational treatment for hot flashes. Candidates must be 40-64, must have multiple daily hot flashes with sweating, and cannot have had a hysterectomy or a menstrual period for at least six months. Participants will receive study-related medication, examinations, and laboratory tests at no charge, and may be compensated for time and travel.

The research site is in West Palm Beach, Fla.

More information

Please see


Copyright 2006 CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.